Stifel reiterates Kamada stock Buy rating on biosimilar expansion
Stifel reiterated a Buy rating and $11.00 price target on Kamada (KMDA), citing two new biosimilar launches. The stock has declined 8% in a week but the target implies 38% upside. Kamada plans to launch more biosimilars, aiming for $20M-$25M in sales by 2030. The company also secured a $50M plasma supply deal and presented positive CYTOGAM study results.
How this was made
The 30-second read
Why it matters
Analyst reiteration reinforces a bullish view but adds little new information beyond the product launches already disclosed.
Market read
The article provides a modest analyst endorsement for KMDA, offering limited trading impetus.
What to watch
Potential regulatory delays or market adoption challenges for the new biosimilars could limit upside.
Background
Kamada Ltd. (NASDAQ:KMDA) is a specialty pharma focused on biosimilars and plasma products, recently expanding its portfolio.
Ticker impact
Stifel reiterated a Buy rating and $11 price target for Kamada after announcing two new biosimilar launches and a plasma supply deal.
likely upward pressure as investors price in the higher target and new product pipeline.
The rating reiteration adds a modest catalyst but the news is not a primary disclosure; impact is limited to sentiment.
Market effects
Highlights continued growth in the biosimilar segment, but limited broader sector impact.
Primarily relevant to Israeli and MENA specialty pharma markets.
Low; the story is company‑specific with modest global significance.
Counterpoint
The price target may be overly optimistic given the modest revenue outlook and competitive biosimilar landscape.
Key entities
- companyKamada Ltd.
Specialty pharmaceutical company developing biosimilars.
- analystStifel
Equity research firm providing the Buy rating and price target.
